6C2O
Crystal structure of HCV NS3/4A protease variant Y56H in complex with danoprevir
Summary for 6C2O
Entry DOI | 10.2210/pdb6c2o/pdb |
Descriptor | NS3 protease, (2R,6S,12Z,13aS,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-14a-[(cyclopropylsulfonyl)carbamoyl]-5,16-dioxo-1,2,3,5,6,7,8 ,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoro-2H-isoindole-2-carboxylate, ZINC ION, ... (5 entities in total) |
Functional Keywords | ns3/4a protease, hepatitis c virus, drug resistance, protease inhibitor, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor |
Biological source | Hepatitis C virus |
Total number of polymer chains | 1 |
Total formula weight | 21880.10 |
Authors | Matthew, A.N.,Schiffer, C.A. (deposition date: 2018-01-08, release date: 2019-01-16, Last modification date: 2023-10-04) |
Primary citation | Matthew, A.N.,Schiffer, C.A. Clinical signature variant of HCV NS3/4A protease uses a novel mechanism to confer resistance To be Published, |
Experimental method | X-RAY DIFFRACTION (1.179 Å) |
Structure validation
Download full validation report